Diagnostics

Neurodegeneration

INNOTEST^® PHOSPHO-TAU_(181P)

INNOTEST^® PHOSPHO-TAU(181P) is an ELISA microplate assay for the quantitative determination of human tau, phosphorylated at threonine 181, in human cerebrospinal fluid (CSF).

CSF-phospho-tau is a unique biomarker that can aid differentiation between Alzheimer’s disease and other primary dementias such as dementia with Lewy bodies (1,2).

Article number: 80297 (3V), 80317 (96T)

The CE-marked kit allows easy, reliable, and specific quantification of CSF-phospho-tau181P. Higher specificity for Alzheimer’s disease versus non-AD dementia (eg, dementia with Lewy bodies) allows improved differential diagnosis.

Features & Benefits

• User-friendly enzyme immunoassay
  
  
• Minimum number of handling steps
  
  
• Small sample volume: 75 µL CSF. Duplicate testing is strongly recommended and requires
  2 x 75 µL CSF
  
  
• Reproducible results within the standards range
  
  
• Lowest detection limit: 15.6 pg/mL
  Standards range: 15.6 to 500 pg/mL
  Normal working range: 25 to 150 pg/mL

Publications

• CSF-phospho-tau (181P) as a promising marker for discriminating Alzheimer’s disease from dementia with Lewy bodies.
• Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
• Phosphorylated tau in cerebrospinal fluid as marker for Creutzfeldt-Jacob disease.
• Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations.
• CSF markers for incipient Alzheimer's disease.
• Standardization and evaluation of INNOTEST^® PHOSPHO-TAU(181P) for the detection of tau, phosphorylated at threonine 181, in cerebrospinal fluid.
• CSF markers for the diagnosis of Alzheimer’s disease.
• Effects of cholinesterase inhibitors on Alzheimer’s disease biomarkers.
• Value of CSF beta-amyloid(1-42) and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
• Discrimination of dementia with Lewy bodies from Alzheimer’s disease via determination of the phospho-tau concentration in cerebrospinal fluid

Background

1. Vanmechelen E, Van Kerschaver E, Blennow K, De Deyn PP, Galasko D, Parnetti L, et al. CSF-phospho-tau (181P) as a promising marker for discriminating Alzheimer’s disease from dementia with Lewy bodies. In: Iqbal K, Sisodia SS, Winblad B. Alzheimer’s disease: Advances in etiology, pathogenesis and therapeutics. Chichester: John Wiley & Sons; 2001. p. 285-291.
2. De Vreese K, Blennow k, Andreasen N, Sindic C, Ivanoiu A, Hampel H, et al. Discrimination of dementia with Lewy bodies from Alzheimer’s disease via determination of the phospho-tau concentration in cerebrospinal fluid. 18th International Conference of Alzheimer’s Disease. Barcelona, Spain, October 23-26, 2002.

Additional useful information about Alzheimer’s disease can be found on the following websites:
The Alzheimer forum site:
http://www.alzforum.org/new/detail.asp?id=875
http://www.alzforum.org/new/detail.asp?id=804
http://www.alzforum.org/new/detail.asp?id=709

Customer support

For all inquiries regarding Innogenetics products and instrumentation, we offer the services of our customer support team. This team of technical experts is committed to dealing with

• General inquiries
• Technical assistance
• Complaint resolution

The customer support team is designed to be your principle point of contact. They will ensure that the appropriate person handles all product-related inquiries. For this service please contact us via e-mail, call us (+32-9 329 16 11), or fax (+32-9 329 17 75).